C5 and viral infectious disease: Employing robust pharmacovigilance algorithms (Montastruc et al., 2011; Bate and Evans, 2009), we detected significant disproportionality signals for viral infections, including influenza, herpes zoster, and gastroenteritis viral, most notably with C5 inhibitors.